MissionIR Articles

The National Institute of Health aims to supports biomedical science and behavioral research through the pursuit of knowledge of the biology and behavior of living systems and to then apply that knowledge to “extend healthy…

VistaGen Therapeutics stands at the forefront today of the rapidly developing world of stem cell technology, with a tight portfolio of IP that cuts hard and fast across multiple, critical applications in the areas of…

VistaGen Therapeutics is focused on drug rescue and regenerative medicine, applying its pluripotent stem cell technology toward the discovery of small molecule drugs and biologics that trigger the endogenous growth and healing processes that enable…

VistaGen Therapeutics is a biotechnology company mainly focusing on human pluripotent stem cell (hPSC) technology for drug rescue and regenerative medicine. Human pluripotent cells are the building blocks of all cells of the human body.…

VistaGen Therapeutics, a biotech company using proprietary pluripotent stem cell technology for drug rescue and regenerative medicine, has received from the Canadian Intellectual Property Office a Notice of Allowance for Canadian patent No. 2,684,022, entitled…

For 16 years, California-based VistaGen Therapeutics has worked with key collaborators to develop proprietary technologies which produce several types of several types of mature, functional adult human cells for drug rescue application. In its drug…

VistaGen Therapeutics is a stem cell company which centers its attention on drug rescue and regenerative medicine – a type of tissue engineering and molecular biology that deals with the process of replacing, engineering or…

VistaGen is a biotech company applying pluripotent stem cell technology for drug rescue and regenerative medicine with a primary focus on heart and liver cells. A pluripotent stem cell, such as an embryonic stem cell,…

VistaGen Therapeutics, a biotechnology company applying pluripotent stem cell technology for drug rescue and regenerative medicine, reports that it is now a member of the Cardiac Safety Technical Committee, Cardiac Stem Cell Working Group, and…

VistaGen Therapeutics stands at the forefront of the biotech industry today with their human pluripotent stem cell (hPSC) differentiation capabilities, which allow the company to produce a wide variety of functional adult human cells that…

VistaGen Therapeutics is a 16-year-old biotechnology company that uses human pluripotent stem cell (hPSC) technology to devise a new platform for new drug development with a core focus on drug rescue. Their commercial platforms consist…

VistaGen Therapeutics is a biotechnology company whose focus is on applying pluripotent stem cell technology for drug rescue and regenerative medicine. The company, which is based out of San Francisco, has been in the business…

In the late 1990s, VistaGen Therapeutics’ founders established the company to make their dreams a reality. The founders wanted to create human cell-based biological assay systems that provide reliable insight into the healing and harmful…

Today, VistaGen Therapeutics announced that it has received broader intellectual property protection for its stem cell technology platform. The United States Patent and Trademark Office recently issued a notice of allowance (NOA) for U.S. Patent…

VistaGen Therapeutics is a San Francisco-based biotechnology company that focuses on human stem cell technology for the purposes of drug rescue, predictive toxicology, and drug metabolism screening. The company was founded in 1998 and has…

VistaGen’s human pluripotent stem cell (hPSC) based approach to salvaging the massive outlays that are otherwise eaten when a once-promising drug candidate is dropped due to unexpected heart or liver toxicity complications (or preemptively preventing…

Today, VistaGen Therapeutics announced its membership in the Cardiac Research Safety Consortium, a public-private partnership launched in 2006 through an FDA Critical Path Initiative Memorandum of Understanding with Duke University. The consortium aims to support…

VistaGen Therapeutics believes the U.S. pharmaceutical industry is facing a drug discovery and development crisis. In 2012, the U.S. pharmaceutical industry invested over $48 billion in research and development. As a result the Center for…

VistaGen Therapeutics is keenly aware that despite decades of well-intentioned awareness and prevention campaigns, heart disease is still the leading cause of death for both men and women. The disease kills more than 600,000 Americans…

Despite decades of awareness and prevention campaigns, heart disease remains the No. 1 cause of death for both men and women, killing more than 600,000 Americans each year. Roughly 49 percent of Americans have at…